New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:43 EDTAVNR, PPG, CLSN, OREX, END, AMKR, ACHN, ATML, HLT, MTGEHigh option volume stocks
High option volume stocks: CLSN HLT AMKR PPG ATML END AVNR ACHN OREX MTGE
News For CLSN;HLT;AMKR;PPG;ATML;END;AVNR;ACHN;OREX;MTGE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
08:03 EDTCLSNCelsion announces preclinical data confirming delivery of RNA to lung cells
Subscribe for More Information
May 14, 2015
10:00 EDTATMLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:14 EDTATMLAtmel upgraded to Overweight at Stephens
As previously reported, Stephens upgraded Atmel to Overweight from Equal Weight, saying that management has been taking the right steps to lower spending and the company is levered to the fast growing Internet of Things space. The firm raised its price target on Atmel shares to $10 from $8.50.
07:25 EDTATMLAtmel upgraded to Overweight from Equal Weight at Stephens
Subscribe for More Information
May 13, 2015
17:11 EDTCLSNCelsion announces ASCO 2015 GEN-1 Immunotherapy Phase 1b results
Celsion Corporation announced that results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented in poster session at the 2015 American Society of Clinical Oncology meeting in Chicago on Saturday, May 30th. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. Dr. Premal H. Thaker, M.D., associate professor at Washington University and Siteman Cancer Center in St. Louis and a principal investigator for the study, highlighted the results in an abstract titled, "A Phase I Study of Intraperitoneal EGEN-001 in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer." The abstract is available on the ASCO website. The Phase 1b dose escalating study enrolled 16 patients with platinum-resistant ovarian cancer and evaluated the safety, tolerability and efficacy of GEN-1 in combination with pegylated doxorubicin as well as the effect of intraperitoneal injection of GEN-1 on IL-12 and tumor cytokine levels. Patients received pegylated liposomal doxorubicin on day 1 and GEN-1 on days 1, 8, 15 and 22. This treatment regimen was repeated every 28 days in the absence of disease progression or unacceptable toxicity. The findings demonstrated an overall clinical benefit of 57% for all treatment arms, with a partial response rate of 21% and a stable disease rate of 36%. The overall clinical benefit observed at the highest dose level was 86%. GEN-1 was well tolerated, with no dose limiting toxicities and no overlapping toxicities between GEN-1, its subsequent immune system activation and pegylated doxorubicin.
08:08 EDTOREXOrexigen price target lowered to $8 from $11 at Leerink
Subscribe for More Information
07:32 EDTATMLCLSA to hold a conference
Subscribe for More Information
May 12, 2015
19:33 EDTOREXOrexigen provides update on Contrave collaboration with Takeda
Subscribe for More Information
19:32 EDTOREXOrexigen provides statement on termination of Light Study
Subscribe for More Information
17:54 EDTOREXOn The Fly: After Hours Movers
Subscribe for More Information
17:52 EDTOREXTakeda requesting Orexigen to pay cost of second heart trial, Bloomberg says
Subscribe for More Information
15:17 EDTOREXOrexigen weakness a buying opportunity, says Piper Jaffray
Subscribe for More Information
08:38 EDTOREXTakeda and Orexigen accept recommendation of the ESC
Subscribe for More Information
08:04 EDTCLSNCelsion reports Q1 EPS (35c), consensus (33c)
Reports Q1 revenue $125K, consensus $125K
May 11, 2015
09:27 EDTHLTHilton 90M share Spot Secondary priced at $29.85
The deal range was $29.85-$29.95. Deutsche Bank, BofA/Merrill and Citigroup acted as joint book running managers for the offering.
08:13 EDTHLTHilton 90M share Spot Secondary, price range $29.85-$29.95
Hilton is offering 90M shares of common stock with a range of $29.85-$29.95 for affiliates of The Blackstone Group in a deal that is expected to price before the open. Deutsche Bank, BofA/Merrill and Citigroup are acting as joint book running managers for the offering.
06:17 EDTHLTHilton files to sell 90M shares of common stock for The Blackstone Group
Deutsche Bank Securities, BofA Merrill Lynch and Citigroup are serving as joint book-running managers for the offering.
06:16 EDTHLTHilton files 544.6M share automatic equity shelf for The Blackstone Group
Subscribe for More Information
May 8, 2015
12:46 EDTHLTMarriott CEO sees four potential outcomes for Hilton, Hotel News Now says
Marriott CEO Arne Sorenson laid out four possible outcomes for Starwood (HOT), which is exploring strategic alternatives, Hotel News Now reports, citing comments from the Arabian Hotel Investment Conference in Dubai. One outcome is Marriott or Hilton (HLT) buying Starwood, which Sorenson downplayed, according to the website. The others options include Starwood acquiring another company, getting bought out by a buyer from the Middle East or Asia and maintaining the current ownership structure. Reference Link
07:08 EDTOREXOrexigen reports Q1 EPS (14c), consensus (14c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use